Comparing Two Bemiparin Dose Regimens to Prevent Blood Clots After Surgery in Morbidly Obese Adults

What this Trial Is About

This research aims to evaluate two different doses of Bemiparin, a low-molecular-weight heparin, for preventing venous thromboembolism VTE in morbidly obese patients undergoing non-orthopedic surgery. Morbid obesity is linked to a high risk of VTE, especially after surgery, and fixed doses of anticoagulants may not provide optimal protection. The study seeks to find effective and safe thromboprophylaxis strategies tailored to this high-risk group. Participants will receive one of two Bemiparin doses 3,500 IU or 5,000 IU, administered by injection under the skin 6 hours after surgery. Treatment continues daily for up to 10 days for moderate and high-risk patients, and up to 30 days for very high-risk patients, based on the Caprini risk classification for VTE. The study excludes orthopedic surgery patients to focus on non-orthopedic surgical cases. During the study, participants will be monitored for VTE events such as deep vein thrombosis or pulmonary embolism up to 30 days after surgery. Researchers will also assess side effects from both dosing regimens. Participants will undergo regular follow-up visits and evaluations to track outcomes and ensure safety throughout the study period.

Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients